407 related articles for article (PubMed ID: 32243841)
1. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
2. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
[TBL] [Abstract][Full Text] [Related]
3. Protocol for establishing organoids from human ovarian cancer biopsies.
Maenhoudt N; Vankelecom H
STAR Protoc; 2021 Jun; 2(2):100429. PubMed ID: 33870230
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
5. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
6. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
Chen YA; Lu CY; Cheng WF; Kuo KT; Yu CW; Ho HN; Chen HF; Pan SH
BMC Cancer; 2022 Sep; 22(1):967. PubMed ID: 36085021
[TBL] [Abstract][Full Text] [Related]
7. Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing.
Psilopatis I; Sykaras AG; Mandrakis G; Vrettou K; Theocharis S
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672509
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
9. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
10. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
11. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
12. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W; Gall-Mas L; Falco MM; Li Y; Lavikka K; Kriegbaum MC; Oikkonen J; Bulanova D; Pietras EJ; Voßgröne K; Chen YJ; Erkan EP; Dai J; Lundgren A; Grønning Høg MK; Larsen IM; Lamminen T; Kaipio K; Huvila J; Virtanen A; Engelholm L; Christiansen P; Santoni-Rugiu E; Huhtinen K; Carpén O; Hynninen J; Hautaniemi S; Vähärautio A; Wennerberg K
Dev Cell; 2023 Jun; 58(12):1106-1121.e7. PubMed ID: 37148882
[TBL] [Abstract][Full Text] [Related]
13. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.
Hoffmann K; Berger H; Kulbe H; Thillainadarasan S; Mollenkopf HJ; Zemojtel T; Taube E; Darb-Esfahani S; Mangler M; Sehouli J; Chekerov R; Braicu EI; Meyer TF; Kessler M
EMBO J; 2020 Mar; 39(6):e104013. PubMed ID: 32009247
[TBL] [Abstract][Full Text] [Related]
14. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
15. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
Kumar S; Raina M; Tankay K; Ingle GM
Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
[TBL] [Abstract][Full Text] [Related]
17. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.
Lõhmussaar K; Kopper O; Korving J; Begthel H; Vreuls CPH; van Es JH; Clevers H
Nat Commun; 2020 May; 11(1):2660. PubMed ID: 32461556
[TBL] [Abstract][Full Text] [Related]
18. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
19. High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
Vias M; Morrill Gavarró L; Sauer CM; Sanders DA; Piskorz AM; Couturier DL; Ballereau S; Hernando B; Schneider MP; Hall J; Correia-Martins F; Markowetz F; Macintyre G; Brenton JD
Elife; 2023 May; 12():. PubMed ID: 37166279
[TBL] [Abstract][Full Text] [Related]
20. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
Burkhart RA; Baker LA; Tiriac H
Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
